Novus Therapeutics, Inc. (NVUS) financial statements (2020 and earlier)

Company profile

Business Address 19900 MACARTHUR BLVD.
IRVINE, CA 92612
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments913172324105
Cash and cash equivalents913172324105
Restricted cash and investments  00  
Receivables0     
Prepaid expense112   
Other current assets010   
Other undisclosed current assets0  6432
Total current assets:1014193067108
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment000000
Intangible assets, net (including goodwill) 22   
Goodwill 22   
Restricted cash and investments   000
Other noncurrent assets11  0 
Total noncurrent assets:132010
TOTAL ASSETS:1117213068108
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities121365
Accounts payable010011
Accrued liabilities000253
Employee-related liabilities010  1
Debt0     
Postemployment benefits liability  1   
Other undisclosed current liabilities0    (1)
Total current liabilities:121364
Noncurrent Liabilities
Long-term debt and lease obligation0     
Operating lease, liability0
Liabilities, other than long-term debt    0 
Other liabilities    0 
Other undisclosed noncurrent liabilities   0  
Total noncurrent liabilities:0  00 
Other undisclosed liabilities 10   
Total liabilities:131364
Stockholders' equity
Stockholders' equity attributable to parent914192762104
Common stock000000
Additional paid in capital675647196193190
Accumulated other comprehensive loss   (0)(0) 
Accumulated deficit(58)(42)(28)(169)(131)(86)
Total stockholders' equity:914192762104
TOTAL LIABILITIES AND EQUITY:1117213068108

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(16)(14)(13)(38)(45)(23)
Operating loss:(16)(14)(13)(38)(45)(23)
Nonoperating income (expense)0(0)0  0
Other nonoperating income (expense)0(0)0   
Net loss:(16)(14)(13)(38)(45)(23)
Other undisclosed net income attributable to parent   00 
Net loss available to common stockholders, diluted:(16)(14)(13)(38)(45)(23)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(16)(14)(13)(38)(45)(23)
Comprehensive loss:(16)(14)(13)(38)(45)(23)
Other undisclosed comprehensive income, net of tax, attributable to parent   00 
Comprehensive loss, net of tax, attributable to parent:(16)(14)(13)(38)(45)(23)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: